NCT00356967

Brief Summary

The primary objective is to demonstrate the efficacy of dianicline as an aid to smoking cessation in cigarette smokers. The main secondary objectives are: to assess the craving for cigarettes, nicotine withdrawal symptoms and the safety of dianicline.

Trial Health

93
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
602

participants targeted

Target at P75+ for phase_3

Timeline
Completed

Started Jun 2006

Shorter than P25 for phase_3

Geographic Reach
6 countries

6 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2006

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

July 26, 2006

Completed
1 day until next milestone

First Posted

Study publicly available on registry

July 27, 2006

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2007

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2007

Completed
Last Updated

December 19, 2008

Status Verified

December 1, 2008

Enrollment Period

1 year

First QC Date

July 26, 2006

Last Update Submit

December 18, 2008

Conditions

Keywords

smokingcessationtobaccosmoking cessationtobacco use cessation

Outcome Measures

Primary Outcomes (3)

  • to assess the continuous abstinence from tobacco smoking at every visit during the last four weeks of treatment through direct inquiry of patients

  • exhaled carbon monoxide testing

  • and plasma cotinine measurements

Secondary Outcomes (2)

  • questionnaire of smoking urge

  • Hughes and Hatsukami Minnesota Withdrawal Scale to measure nicotine withdrawal

Interventions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Outpatients over the legal age smoking at least 10 cigarettes per day for at least 2 months

You may not qualify if:

  • Insufficient level of motivation
  • Another participant in the household
  • Patients with current psychotic disorder or major depressive disorder
  • The investigator will evaluate whether there are other reasons why a patient may not participate.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (6)

Sanofi-Aventis Administrative Office

Diegem, Belgium

Location

Sanofi-Aventis Administrative Office

Hørsholm, Denmark

Location

Sanofi-Aventis Administrative Office

Paris, France

Location

Sanofi-Aventis Administrative Office

Lysaker, Norway

Location

Sanofi-Aventis Administrative Office

Barcelona, Spain

Location

Sanofi-Aventis Administrative Office

Bromma, Sweden

Location

Related Publications (1)

  • Livingstone-Banks J, Fanshawe TR, Thomas KH, Theodoulou A, Hajizadeh A, Hartman L, Lindson N. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2023 May 5;5(5):CD006103. doi: 10.1002/14651858.CD006103.pub8.

Related Links

MeSH Terms

Conditions

SmokingSmoking CessationTobacco Use Cessation

Interventions

dianicline

Condition Hierarchy (Ancestors)

BehaviorHealth Behavior

Study Officials

  • ICD CSD

    Sanofi

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

July 26, 2006

First Posted

July 27, 2006

Study Start

June 1, 2006

Primary Completion

June 1, 2007

Study Completion

June 1, 2007

Last Updated

December 19, 2008

Record last verified: 2008-12

Locations